Inovio Shares Down After Co. Says AstraZeneca Will Discontinue Some Collaboration Deal Activities

   By Stephen Nakrosis

Shares of Inovio Pharmaceuticals Inc. (INO) are falling in Tuesday's after-hours action, following an announcement by the company that it was informed AstraZeneca plans to discontinue activities on research collaboration programs from an August 7, 2015, agreement, with the exception of MEDI0457.

At 5:49 p.m. ET, Inovio shares had lost 6.69% to trade at $2.92. Inovio's shares lost ground in the day's regular trading session as well, finishing 3.68% lower to close at $3.14 per share.

Inovio said it received notification from MedImmune Limited about the decision. The company also said AstraZeneca will continue to "evaluate MEDI0457, in combination with its PD-L1 checkpoint inhibitor, durvalumab, in multiple Phase 2 clinical trials in patients with cancers associated with human papillomavirus, or HPV."

--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

(END) Dow Jones Newswires

May 28, 2019 18:22 ET (22:22 GMT)

Inovio Pharmaceuticals (NASDAQ:INO)
Historical Stock Chart
From Apr 2024 to May 2024